Source: Contract Pharma

Domain Therapeutics: Domain Therapeutics & Chime Biologics Sign Manufacturing Service Agreement

Chime Biologics to ensure stable cell line development and DT-7012 candidate manufacturing to support clinical trials.

Read full article »
Domain Therapeutics's Competitors | Domain Therapeutics's News | Domain Therapeutics's Financials
Stay up-to-date with the latest news on Domain Therapeutics
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Sean A. MacDonald's photo - CEO of Domain Therapeutics

CEO

Sean A. MacDonald

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Domain Therapeutics